decitabine dosing regimens in older aml patients: 5-day vs. 10-day, is there a difference?
Published 6 years ago • 1.7K plays • Length 2:33Download video MP4
Download video MP3
Similar videos
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
5:24
10-day decitabine vs 3 7 chemotherapy followed by allohsct in older & fit patients with aml
-
2:16
rationale for 10-day decitabine with venetoclax for high-risk aml
-
1:54
risk-adapted therapy: three-day versus five-day oral decitabine in patients with mds
-
6:21
decitabine and venetoclax for aml
-
2:18
the all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with aml
-
2:23
oral combination of astx727 (decitabine/cedazuridine) plus ven for older/unfit patients with aml
-
1:27:40
what is mds and how do we determine prognosis?
-
13:02
introduction to hematology |medical laboratory science
-
43:10
venetoclax plus gilteritinib for flt3-mutated relapsed/refractory acute myeloid leukemia
-
2:06
onvansertib with cytarabine or decitabine for r/r aml
-
2:05
alnuctamab: improved route of administration and optimized dose level & dosing schedule
-
1:32
onvansertib plus decitabine for patients with r/r aml
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
0:45
oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with aml
-
2:05
venetoclax with decitabine for high-risk aml and mds
-
0:23
types of doctors
-
8:35
effect of bmt status on decitabine plus ipilimumab in r/r mds/aml
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml
-
1:17
decitabine, venetoclax and ponatinib in patients with advanced cml and ph aml
-
0:55
the role of rna modifications in mds and aml